Christina Coughlin
Vorstandsvorsitzender bei AVACTA GROUP PLC
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Trevor Nicholls | M | 67 | 11 Jahre | |
| Paul Fry | M | 58 | 4 Jahre | |
| Eliot Forster | M | 58 | 9 Jahre | |
| José Eduardo Vidal | M | - |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 3 Jahre |
| Tony Gardiner | M | 53 | 8 Jahre | |
| Kristine Peterson | F | 64 | 7 Jahre | |
| Michael Vinegrad | M | - | 10 Jahre | |
| Graeme Bell | M | 57 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 4 Jahre |
| Garry Nicholson | M | 69 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 Jahre |
| Neil Bell | M | - | 4 Jahre | |
| James Jogerst | M | - | 3 Jahre | |
| Shaun Chilton | M | 57 | 1 Jahre | |
| Matt Johnson | M | - | 11 Jahre | |
| Patrick M. Gray | M | 75 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 Jahre |
| Jorge Conde | M | 47 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 Jahre |
| Mark Goldberg | M | 69 | 3 Jahre | |
| Simon Bennett | M | - | 1 Jahre | |
| Marissa Hanify | F | - | 4 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Dannielle Appelhans | F | 41 | 2 Jahre | |
| Alastair Smith | M | - | 20 Jahre | |
| James Noble | M | 65 | 7 Jahre | |
| Andrew Hotchkiss | M | - | - | |
| Eva-Lotta Allan | F | 65 | 5 Jahre | |
| Mojirade James | F | 57 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 3 Jahre |
| Jose Carmona | M | 51 | 2 Jahre | |
| Thomas Wickham | M | - | 4 Jahre | |
| Mark F. Boshar | M | - | 3 Jahre | |
| Christopher L. Carpenter | M | 68 | 3 Jahre | |
| Rob Ford | M | - | 2 Jahre | |
| Chris Miller | M | - | 9 Jahre | |
| Kris Elverum | M | - | 2 Jahre | |
| Abigail Bracha | M | - | 2 Jahre | |
| Elhan Webb | F | - | - | |
| Andrew Oh | M | 53 | 3 Jahre | |
| Laurence Turka | M | 66 | 3 Jahre | |
| Mark Hernon | M | - | 1 Jahre | |
| James Sandy | M | - | - | |
| Laura Wade-Gery | F | 59 | - | |
| Shah Hussain | M | 59 | 3 Jahre | |
| Sandy Matalonis | F | - |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 1 Jahre |
| Joanne Soundy | F | - | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigtes Königreich | 21 | 51,22% |
| Vereinigte Staaten | 20 | 48,78% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Christina Coughlin
- Persönliches Netzwerk
